Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Acronyms BRIGAROS
- 19 Nov 2021 Status changed from recruiting to completed.
- 04 Oct 2021 Planned End Date changed from 1 Sep 2021 to 17 Oct 2021.
- 04 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 17 Oct 2021.